• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    Emergent Biosolutions Unveils Q1 2026 Financial Performance

    FIRSTWORD PHARMA

    Emergent BioSolutions Partners with BC to Supply Narcan Nasal

    GLOBENEWSWIRE

    Emergent BioSolutions Launches NARCAN Nasal Spray Case

    GLOBENEWSWIRE

    Emergent BioSolutions to Join International Preparedness Conf

    GLOBENEWSWIRE

    Emergent Bio Announces Appointment of John D. Fowler, Jr.

    GLOBENEWSWIRE

    Emergent BioSolutions Secures $140M Govt Contracts Awards

    GLOBENEWSWIRE

    Emergent Announces New $50 M Stock Repurchase Program

    GLOBENEWSWIRE

    Emergent Biosolutions Gets FDA Nod For NARCAN Nasal Spray

    GLOBENEWSWIRE

    Emergent Biosolutions To Release Q4 & Full Year 2025 Financials

    GLOBENEWSWIRE

    NY Files Insider Trading Lawsuit Vs. Former Emergent CEO Kramer

    FIERCE PHARMA

    Emergent Biosolutions Gets FDA Nod For NARCAN Nasal Spray

    GLOBENEWSWIRE

    Emergent BioSolutions Repays $100M Term Loan

    GLOBENEWSWIRE

    Emergent Biosolutions, PANTHER Support Africa Cdc`s Mpox Study

    GLOBENEWSWIRE

    Emergent Biosolutions To Present At J.P. Morgan Healthcare

    GLOBENEWSWIRE

    Emergent Biosolutions Celebrates 10 Years Of NARCAN Nasal Spray

    GLOBENEWSWIRE

    Emergent Biosolutions Board Member Dr. Louis W. Sullivan Retires

    GLOBENEWSWIRE

    Emergent Biosolutions To Release Q3 2025 Financial Results

    GLOBENEWSWIRE

    Emergent BioSolutions Gets $29M MCM Orders from Govt Partner

    GLOBENEWSWIRE

    Emergent BioSolutions Joins Investor Conferences

    GLOBENEWSWIRE

    Emergent Bio Solutions Reports Strong Second Quarter 2025

    GLOBENEWSWIRE

    Emergent Praises Over-the-Counter Naloxone in U.S. House

    GLOBENEWSWIRE

    Emergent BioSolutions` Q2 2025 Financial Results Due August 6

    GLOBENEWSWIRE

    Emergent BioSolutions Expands NARCANDirect to Offer Kloxxado Kits

    GLOBENEWSWIRE

    Emergent BioSolutions Announces Addition to Russell 3000® Index

    GLOBENEWSWIRE

    Emergent BioSolutions Q1 2025 Financial Results

    GLOBENEWSWIRE

    Emergent BioSolutions to Report Q1 2025 Results on May 7

    GLOBENEWSWIRE

    Emergent BioSolutions Announces Stock Repurchase Program

    GLOBENEWSWIRE

    Emergent BioSolutions` Equity Grant under NYSE Rule 303A.08

    GLOBENEWSWIRE

    Emergent Reports Q4, Full-Year 2024 Financial Results

    GLOBENEWSWIRE

    Emergent BioSolutions to Report Q4 and Full Year 2024 Results

    GLOBENEWSWIRE

    Emergent To Present At 43rd J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Emergent BioSolutions Reports Q3 2024 Financial Results

    GLOBENEWSWIRE

    Emergent BioSolutions Appoints Dr. Simon Lowry as CMO

    GLOBENEWSWIRE

    Emergent BioSolutions Q3 2024 Results and Call on November 6

    GLOBENEWSWIRE

    Emergent Demonstrates Commitment To NARCAN Access

    GLOBENEWSWIRE

    Emergent BioSolutions Closes $100M Asset-Backed Loan Facility

    GLOBENEWSWIRE

    Emergent BioSolutions Executes Contract Options For TEMBEXA

    GLOBENEWSWIRE

    Emergent BioSolutions Settles Securities Class Action Litigation

    GLOBENEWSWIRE

    Emergent BioSolutions Refinances Debt, Strengthens Financial Profile

    GLOBENEWSWIRE

    Emergent BioSolutions Expands Ready To Rescue Opioid Emergency Initiative

    GLOBENEWSWIRE

    Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent

    PRESS RELEASE

    Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution

    GLOBENEWSWIRE

    Emergent BioSolutions Reports Second Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Emergent BioSolutions Sells RSDL® Kit To SERB For $75 Million

    GLOBENEWSWIRE

    Emergent BioSolutions Launches Opioid Emergency Campaign With Emmitt Smith

    GLOBENEWSWIRE

    Emergent, ex-NFL star show how to tackle opioid overdoses in new ad blitz

    FIERCE PHARMA

    Emergent BioSolutions To Release Q2 2024 Results On August 6

    GLOBENEWSWIRE

    Emergent BioSolutions Extends Shelf-Life For NARCAN Spray In Canada

    GLOBENEWSWIRE

    Emergent BioSolutions Continues Multi-Year Transformation Plan

    GLOBENEWSWIRE

    Emergent BioSolutions Awarded $250M+ For Medical Countermeasure Products

    GLOBENEWSWIRE

    Emergent bags $250M in contract modifications to help boost US supply

    FIERCE PHARMA

    Emergent BioSolutions Sells Baltimore-Camden Site To Bora Pharma For $30M

    PRESS RELEASE

    Emergent Drives Progress Against Opioid Epidemic On Naloxone Day

    GLOBENEWSWIRE

    Emergent BioSolutions Virtual Stockholder Meeting On May 23

    GLOBENEWSWIRE

    Survey Shows Need For Expanded Naloxone Access, Awareness

    GLOBENEWSWIRE

    Emergent Bio Announces Strategic Operational Changes

    GLOBENEWSWIRE

    Emergent BioSolutions Reports First Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Emergent to cut 300 jobs, shutter 2 facilities in major overhaul

    FIERCE PHARMA

    Emergent BioSolutions Announces Amendment to its Existing Credit Facility

    GLOBENEWSWIRE

    Emergent Bio Q1 2024 Results, Call On May 1

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.